Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Endocrine

Volumn 51, Issue 3, 2016, Pages 417-428

  Giugliano, Dario ^a   Chiodini, Paolo ^a   Maiorino, Maria Ida ^a   Bellastella, Giuseppe ^a   Esposito, Katherine ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Basal bolus; Insulin regimens; Meta analysis; Premix; Type 2 diabetes

Indexed keywords

GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; PIOGLITAZONE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE DURATION; DRUG INDUSTRY; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; WEIGHT GAIN; DIABETES MELLITUS, TYPE 2; DRUG FORMULATION; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; DRUG COMPOUNDING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84959511533     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0718-3     Document Type: Article

References (42)

1. E.W. Gregg, X. Zhuo, Y.J. Cheng, A.L. AlbrighL, K.M. Narayan, T.J. Thompson, Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985–2011: a modelling study. Lancet Diabetes Endocrinol 2, 867–874 (2014)
2. American Diabetes Association, 7. Approaches to glycemic treatment. Diabetes Care 38(Suppl. 1), S41–S48 (2015)
3. L.W. Turner, D. Nartey, R.S. Stafford, S. Singh, G.C. Alexander, Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012. Diabetes Care 37, 985–992 (2014)
4. K. Esposito, P. Chiodini, G. Bellastella, M.I. Maiorino, D. Giugliano, Proportion of patients at HbA1c target <7 % with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients. Diabetes Obes. Metab. 14, 228–233 (2012)
5. P. de Pablos-Velasco, K.G. Parhofer, C. Bradley, E. Eschwège, L. Gönder-Frederick, P. Maheux, I. Wood, D. Simon, Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin. Endocrinol. (Oxf.) 80, 47–56 (2014)
6. American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, E. Diamant, M. Ferrannini, A.L. Nauck, A. Peters, R. Tsapas, R. Wender, D.R. Matthews, Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35, 1364–1379 (2012)
7. Orals Plus Apidra and LANTUS (OPAL) study group, M.R. Lankisch, K.C. Ferlinz, J.L. Leahy, W.A. Scherbaum, Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes. Metab. 10, 1178–1185 (2008)
8. M.B. Davidson, P. Raskin, R.J. Tanenberg, A. Vlajnic, P. Hollander, A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr. Pract. 17, 395–403 (2001)
9. A.J. Garber, J. Wahlen, T. Wahl, P. Bressler, R. Braceras, E. Allen, R. Jain, Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes. Metab. 8, 58–66 (2006)
10. O. Mosenzon, I. Raz, Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom? Diabetes Care 36(Suppl 2), S212–S218 (2013)
11. B.T. Blak, H.T. Smith, M. Hards, A. Maguire, V. Gimeno, A retrospective database study of insulin initiation in patients with Type 2 diabetes in UK primary care. Diabet. Med. 29, e191–e198 (2012)
12. P.D. Home, M.-P. Dain, N. Freemantle, R. Kawamori, M. Pfohl, S. Brette, V. Pilorget, W.A. Scherbaum, G. Vespasiani, M. Vincent, B. Balkau, Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Res. Clin. Pract. (2015). doi:10.1016/j.diabres.2015.01.030
13. J.L. Li, W. Jia, J. Weng, Glycemic control in insulinized type 2 diabetes patients in China: one-year results from IDMPS. American Diabetes Association 69th Scientific Sessions, New Orleans, 2009
14. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, J.P. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 151, W65–W94 (2009)
15. J. Higgins, D.G. Altman, P.C. Gotzsche, P. Jüni, D. Moher, A.D. Oxman, J. Savovic, K.F. Schulz, L. Weeks, J.A. Sterne, The Cochrane collaboration’s tool for assessing risk of bias in randomized trials. BMJ 343, d5928 (2011)
16. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, H.J. McQuay, Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17, 1–12 (1996)
17. J.P.T. Higgins, S. Green (ed.), Cochrane Handbook for Systematic Reviews of Interventions (The Cochrane Collaboration, 5.1.0. Oxford, 2011)
18. J.J.A.D. Deeks, M.J. Bradburn, Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis, in Systematic Reviews in Health Care, ed. by M.D.-S.G. Egger, D.G. Altman (BMJ Publishing, London, 2001), pp. 285–312
19. R. Malek, F. Ajili, S.H. Assaad-Khalil, A. Shinde, J.W. Chen, E. Van den Berg, Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification. Diabetes Metab. (2014). doi:10.1016/j.diabet.2014.11.002
20. W. Jia, X. Xiao, Q. Ji, K.-J. Ahn, L.-M. Chuang, Y. Bao, C. Pang, L. Chen, F. Gao, Y. Tu, P. Li, J. Yang, Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. Lancet Diabetes Endocrinol. 3, 254–262 (2015)
21. D. Giugliano, M. Tracz, S. Shah, A. Calle-Pascual, C. Mistodie, R. Duarte, R. Sari, V. Woo, A.O. Jiletcovici, J. Deinhard, S.A. Wille, J. Kiljanski, Initiation and gradual intensification of premixed insulin lispro therapy versus basal ± mealtime insulin in patients with type 2 diabetes eating light breakfasts. Diabetes Care 37, 372–380 (2014)
22. F.J. Tinahones, J.L. Gross, A. Onaca, S. Cleall, A. Rodríguez, Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Diabetes Obes. Metab. 16, 963–970 (2014)
23. M.C. Riddle, J. Rosenstock, A. Vlajnic, L. Gao, Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes. Metab. 16, 396–402 (2014)
24. K. Bowering, V.A. Reed, J.S. Felicio, J. Landry, L. Ji, J. Oliveira, A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study. Diabet. Med. 29, e263–e272 (2012)
25. P.A. Levin, Q. Zhang, J.H. Mersey, F.Y. Lee, L.A: Bromberger, M. Bhushan, R. Bhushan, Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design. Clin. Ther. 33, 841–850 (2011)
26. A. Fritsche, M. Larbig, D. Owens, H.U. Häring, GINGER study group, Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes. Metab. 12, 115–123 (2010)
27. W.F. Miser, R. Arakaki, H. Jiang, J. Scism-Bacon, P.W. Anderson, J.L. Fahrbach, Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin. Ther. 32, 896–908 (2010)
28. S.M. Jain, X. Mao, M. Escalante-Pulido, N. Vorokhobina, I. Lopez, L.L. Ilag, Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes. Metab. 12, 967–975 (2010)
29. PREFER Study Group, A. Liebl, R. Prager, K. Binz, M. Kaiser, R. Bergenstal, B. Gallwitz, Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes. Metab. 11, 45–52 (2009)
30. J. Rosenstock, A.J. Ahmann, G. Colon, J. Scism-Bacon, H. Jiang, S. Martin, Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal-bolus (glargine/lispro) therapy. Diabetes Care 31, 20–25 (2008)
31. R.J. Ligthelm, U. Mouritzen, H. Lynggaard, M. Landin-Olsson, C. Fox, C. le Devehat, E. Romero, A. Liebl, Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 114, 511–519 (2006)
32. European Medicines Agency, Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. CPMP/EWP/1080/00 Rev. 1. 14 May 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf. Accessed 27 Apr 2015
33. Food and Drug Administration, Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. draft guidance (2008). http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed 17 Apr 2015
34. D. Giugliano, M.I. Maiorino, G. Bellastella, P. Chiodini, A. Ceriello, K. Esposito, Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7 % in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 34, 510–517 (2011)
35. R. Miao, W. Wei, O. Baser, L. Xie, Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine. Patient Prefer Adherence 7, 951–960 (2013)
36. 4-T Study Group, R.R. Holman, K.I. Thorne, A.J. Farmer, M.J. Davies, J.F. Keenan, S. Paul, J.C. Levy, Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. New Engl. J. Med. 357, 1716–1730 (2007)
37. 4-T Study Group, R.R. Holman, A.J. Farmer, M.J. Davies, J.C. Levy, J.L. Darbyshire, J.F. Keenan, S.K. Paul, Three-year efficacy of complex insulin regimens in type 2 diabetes. New Engl. J. Med. 361, 1736–1747 (2009)
38. D. Giugliano, M.I. Maiorino, G. Bellastella, P. Chiodini, K. Esposito, Treatment regimens with insulin analogues and haemoglobin A1c target of <7 % in type 2 diabetes: a systematic review. Diabetes Res. Clin. Pract. 92, 1–10 (2011)
39. D. Giugliano, M.I. Maiorino, G. Bellastella, M. Petrizzo, A. Ceriello, S. Genovese, K. Esposito, Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither? Endocrine (2015). doi:10.1136/bmjopen-2014-005892
40. G. Dieuzeide, L.M. Chuang, A. Almaghamsi, A. Zilov, J.W. Chen, F.J. Lavalle-González, Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study. Prim Care Diabetes 8, 111–117 (2014)
41. C. Mathieu, F. Storms, J. Tits, T.F. Veneman, I.M. Colin, Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study. Acta Clin. Belg. 68, 28–33 (2013)
42. H.I. Price, M.D. Agnew, J.-M. Gamble, Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review. BMJ Open 5, e006341 (2015)